

Company TranXenoGen Inc
TIDM TXN
Headline Directorate Change
Released 07:00 5 Dec 2002
Number 6861E

TranXenoGen Inc.

Appointment of Non-Executive Chairman

TranXenoGen, Inc. (“TranXenoGen” or the “Company”), the avian transgenic company based in Shrewsbury, Massachusetts and listed on the Alternative Investment Market of the London Stock Exchange (TXN.L), announces the appointment of Mr. Cary Garner to Non-Executive Chairman, effective January 1, 2003. Dr. Tan and Mr. Garner have been TranXenoGen’s Non-Executive Directors and Dr. Tan has been the Non-Executive Chairman since March of 2000. Dr. Kim Tan will continue to assist the company in its development and will remain a Non-Executive Director of TranXenoGen and Chairman of the Audit Committee of the Board of Directors.

Mr. Garner is Vice President and General Manager of Clinical Research Services for PAREXEL International, a leading international clinical research organization based in Waltham, Massachusetts. Prior to joining PAREXEL, Mr. Garner was a Principal and Managing Partner of Cambridge Consulting Group, a firm specializing in transforming innovative, proprietary technologies into operating companies. Mr. Garner has also held positions with IBM and Abbott Laboratories.

George Uveges, President and Chief Executive Officer, commented:

“Dr. Tan has been instrumental in the Company’s development over the last three years as Non-Executive Chairman and we appreciate his past and future contributions. Mr. Garner, who has been a Non-Executive Director and Chairman of the Compensation Committee of the Board of Directors since March 2000, has significant experience in the drug development and regulatory approval area that we will draw upon as we move from a development stage company to an operating company.”

5 December 2002

Enquiries:

TranXenoGen Inc.
Tel: 001 508 936 4214
George Uveges, President and CEO
Email: guveges@tranxenogen.com

College Hill Associates
Tel: 020 7457 2020
Nicholas Nelson

Risk Warning Notice:

TranXenoGen Inc. (symbol TXN.L) is a publicly traded biotechnology company. Its shares are quoted on the Alternative Investment Market of the London Stock Exchange. The Company specializes in avian transgenics for the production of high volume therapeutic proteins. TranXenoGen is a development stage company and, as such, investors should be aware that an investment in the Company involves a substantially high degree of risk.

This press release contains forward-looking statements that can be identified by terminology such as “expects”, “potential”, “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company’s planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.